Journal of Traditional Chinese Medicine ›› 2022, Vol. 42 ›› Issue (1): 23-29.DOI: 10.19852/j.cnki.jtcm.2022.01.002
• Research Articles • Previous Articles Next Articles
Kun MA1(), Yuan YUAN2, Yanxia CHEN2, Bochao YUAN2, Kaili WANG2, Caidie TIAN2, Jiani LI2
Received:
2021-06-16
Accepted:
2021-09-11
Online:
2022-02-15
Published:
2022-01-25
Contact:
Kun MA
About author:
Prof. MA Kun, the department of educational management, China Academy of Chinese Medical Science, Beijing 100007, China. makun12348@sina.comSupported by:
Kun MA, Yuan YUAN, Yanxia CHEN, Bochao YUAN, Kaili WANG, Caidie TIAN, Jiani LI. Efficacy of Bushen Culuan decoction (补肾促卵方) on ovarian follicle and follicular granulosa cells in mice with premature ovarian insufficiency induced by tripterygium wilfordii polyglycoside[J]. Journal of Traditional Chinese Medicine, 2022, 42(1): 23-29.
Group | n | Day –14 | Day 1 | Day 15 | Day 29 |
---|---|---|---|---|---|
Blank | 20 | 18.8±0.7 | 19.3±1.0 | 19.5±0.7a | 19.9±0.7c |
Model | 20 | 19.0±0.5 | 19.4±0.6 | 19.2±0.5 | 19.4±0.5 |
BCD | 20 | 19.2±0.6 | 19.5±0.5 | 19.3±0.9 | 19.70±0.7 |
EV | 20 | 19.1±0.6 | 19.5±0.6 | 19.1±0.3b | 19.5±0.4 |
Table 1 Body weight comparison among each group (g, $bar{x}$ ± s)
Group | n | Day –14 | Day 1 | Day 15 | Day 29 |
---|---|---|---|---|---|
Blank | 20 | 18.8±0.7 | 19.3±1.0 | 19.5±0.7a | 19.9±0.7c |
Model | 20 | 19.0±0.5 | 19.4±0.6 | 19.2±0.5 | 19.4±0.5 |
BCD | 20 | 19.2±0.6 | 19.5±0.5 | 19.3±0.9 | 19.70±0.7 |
EV | 20 | 19.1±0.6 | 19.5±0.6 | 19.1±0.3b | 19.5±0.4 |
Group | n | Days –14-–1 Normal | Days 1-14 | Days 15-28 | Ratio of irregular cycle (%) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal | Prolonged | Stagnate | No cycle | Normal | Prolonged | Stagnate | No cycle | |||||
Blank | 20 | 20a | 19 | 0 | 1 | 0 | 18 | 1 | 1 | 0 | 10 | |
Model | 20 | 20 | 1 | 6 | 3 | 10 | 5 | 7 | 5 | 3 | 75 | |
BCD | 20 | 20 | 2 | 8 | 1 | 9 | 17 | 2 | 0 | 1 | 15b | |
EV | 20 | 20 | 1 | 5 | 6 | 8 | 17 | 1 | 1 | 1 | 15 |
Table 2 Estrous cycle comparison among each group (χ2)
Group | n | Days –14-–1 Normal | Days 1-14 | Days 15-28 | Ratio of irregular cycle (%) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal | Prolonged | Stagnate | No cycle | Normal | Prolonged | Stagnate | No cycle | |||||
Blank | 20 | 20a | 19 | 0 | 1 | 0 | 18 | 1 | 1 | 0 | 10 | |
Model | 20 | 20 | 1 | 6 | 3 | 10 | 5 | 7 | 5 | 3 | 75 | |
BCD | 20 | 20 | 2 | 8 | 1 | 9 | 17 | 2 | 0 | 1 | 15b | |
EV | 20 | 20 | 1 | 5 | 6 | 8 | 17 | 1 | 1 | 1 | 15 |
Group | n | Ovarian index | Uterine index |
---|---|---|---|
Blank | 20 | 0.87±0.35 | 3.42±1.92 |
Model | 20 | 0.72±0.30 | 2.67±0.71 |
BCD | 20 | 0.97±0.28a | 3.41±2.47 |
EV | 20 | 0.84±0.38 | 2.96±1.47 |
Table 3 Gonad index comparison among each group ($bar{x}$ ± s)
Group | n | Ovarian index | Uterine index |
---|---|---|---|
Blank | 20 | 0.87±0.35 | 3.42±1.92 |
Model | 20 | 0.72±0.30 | 2.67±0.71 |
BCD | 20 | 0.97±0.28a | 3.41±2.47 |
EV | 20 | 0.84±0.38 | 2.96±1.47 |
Group | n | FSH (IU/L) | LH (ng/mL) | E2 (ng/L) | AMH (ng/mL) | VEGF (ng/L) | BMP-7 (pg/mL) |
---|---|---|---|---|---|---|---|
Blank | 10 | 9.26±2.36 | 2.18±0.29 | 65.39±9.74b | 14.98±3.12 | 183.48±29.26 | 1202.88±139.00 |
Model | 10 | 11.41±2.39a | 2.38±0.77 | 56.32±10.91 | 14.09±2.49 | 180.36±48.23 | 1078.86±213.40 |
BCD | 10 | 9.89±1.35 | 2.01±0.38 | 64.13±10.72c | 16.95±3.51d | 228.24±48.90e | 1311.59±230.36f |
EV | 10 | 10.11±1.45 | 2.21±0.60 | 57.99±9.06 | 15.56±3.16 | 163.64±39.58 | 1180.40±216.47 |
Table 4 Serum hormone comparison among each group ($bar{x}$ ± s)
Group | n | FSH (IU/L) | LH (ng/mL) | E2 (ng/L) | AMH (ng/mL) | VEGF (ng/L) | BMP-7 (pg/mL) |
---|---|---|---|---|---|---|---|
Blank | 10 | 9.26±2.36 | 2.18±0.29 | 65.39±9.74b | 14.98±3.12 | 183.48±29.26 | 1202.88±139.00 |
Model | 10 | 11.41±2.39a | 2.38±0.77 | 56.32±10.91 | 14.09±2.49 | 180.36±48.23 | 1078.86±213.40 |
BCD | 10 | 9.89±1.35 | 2.01±0.38 | 64.13±10.72c | 16.95±3.51d | 228.24±48.90e | 1311.59±230.36f |
EV | 10 | 10.11±1.45 | 2.21±0.60 | 57.99±9.06 | 15.56±3.16 | 163.64±39.58 | 1180.40±216.47 |
Figure 1 Ovaries of each group (HE Staining, ×200) A: blank group; B: model group; C: BCD group; D: EV group. Arrows: apoptotic cells. White arrows: primordial follicles. Yellow arrows: preantral follicles. Red arrows: antral follicles. Blue arrows: corpus luteum. Black arrows: atretic follicles. Blank group: equal amount of normal saline, 14 d; model group: equal amount of normal saline, 14 d; BCD group: Bushen Culuan decoction, 18.35 g·kg-1·d-1, 14 d; EV group: estradiol valerate intervening group, 0.15 mg·kg-1·d-1, 14 d.
Group | n | Primordial follicles | Preantral follicles | Antral follicles | Preovulatory follicles | Corpus luteum | Atretic follicles |
---|---|---|---|---|---|---|---|
Blank | 10 | 21.60±7.37 | 17.30±3.30 | 3.30±1.57 | 1.50±0.31 | 3.80±1.55 | 1.60±0.34 |
Model | 10 | 10.10±3.81 | 11.10±4.31 | 2.00±1.49 | 0.60±0.22 | 2.10±0.99 | 4.70±0.42 |
BCD | 10 | 21.70±4.19a | 15.20±3.36ab | 3.60±1.65a | 1.30±0.26 | 3.50±1.58a | 1.80±0.47a |
EV | 10 | 18.80±3.68 | 12.80±3.85 | 2.70±1.16 | 0.90±0.23 | 2.40±1.26 | 2.30±0.60 |
Table 5 Unit follicle account comparison among each group ($bar{x}$ ± s)
Group | n | Primordial follicles | Preantral follicles | Antral follicles | Preovulatory follicles | Corpus luteum | Atretic follicles |
---|---|---|---|---|---|---|---|
Blank | 10 | 21.60±7.37 | 17.30±3.30 | 3.30±1.57 | 1.50±0.31 | 3.80±1.55 | 1.60±0.34 |
Model | 10 | 10.10±3.81 | 11.10±4.31 | 2.00±1.49 | 0.60±0.22 | 2.10±0.99 | 4.70±0.42 |
BCD | 10 | 21.70±4.19a | 15.20±3.36ab | 3.60±1.65a | 1.30±0.26 | 3.50±1.58a | 1.80±0.47a |
EV | 10 | 18.80±3.68 | 12.80±3.85 | 2.70±1.16 | 0.90±0.23 | 2.40±1.26 | 2.30±0.60 |
Figure 2 Comparison of ovarian granulosa cell apoptosis (TUNEL staining, ×400) A: blank group; B: model group; C: BCD group; D: EV group. Arrows: apoptotic cells. Blank group: equal amount of normal saline, 14 d; model group: equal amount of normal saline, 14 d; BCD group: Bushen Culuan decoction, 18.35 g·kg-1·d-1, 14 d; EV group: estradiol valerate intervening group, 0.15 mg kg-1·d-1, 14 d. TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; BCD: Bushen Culuan decoction; EV: estradiol valerate.
Figure 3 Comparison of BMP-7 and caspase-3 expressions by Western blot (n = 3) Blank group: equal amount of normal saline, 14 d; model group: equal amount of normal saline, 14 d; BCD group: Bushen Culuan decoction, 18.35 g·kg-1·d-1, 14 d; EV group: estradiol valerate intervening group, 0.15 mg·kg-1·d-1, 14 d. BMP-7: bone morphogenetic protein-7. aP < 0.05, compared with model group. bP < 0.05, compared with EV group. cP < 0.05, compared with model group.
Group | n | BMP-7 | Caspase-3 |
---|---|---|---|
Blank | 3 | 0.520±0.080 | 0.590±0.030 |
Model | 3 | 0.410±0.010 | 0.650±0.010 |
BCD | 3 | 0.640±0.030ab | 0.540±0.040c |
EV | 3 | 0.440±0.020 | 0.610±0.040 |
Table 6 BMP-7 and caspase-3 expressions among each group ($bar{x}$ ± s)
Group | n | BMP-7 | Caspase-3 |
---|---|---|---|
Blank | 3 | 0.520±0.080 | 0.590±0.030 |
Model | 3 | 0.410±0.010 | 0.650±0.010 |
BCD | 3 | 0.640±0.030ab | 0.540±0.040c |
EV | 3 | 0.440±0.020 | 0.610±0.040 |
[1] | Chen ZJ, Tian QJ, Qiao J, et al. Expert consensus of premature ovarian insufficiency clinical diagnosis and treatment. Zhong Hua Fu Can Ke Za Zhi 2017;52:577-81. |
[2] | Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016;31:926-37. |
[3] | Hu YL, Zhang JL, Hou XW, Jin L, Zhang Y. Menopausal hormone therapy and risk of ovarian cancer: a Meta-analysis. Zhong Guo Zhong Liu Xue Za Zhi 2016;22:549-53. |
[4] | Zhang JQ, Zhang Q, Meng L. Overview of estrogen / progestin replacement therapy and breast cancer occurrence risk. Zhong Guo Fu You Bao Jian 2015;30:6669-72. |
[5] | Ye N, Dong XY, Li DH. The progress in apoptotic mechanism of ovarian granulosa cells involved in premature ovarian failure. Shou Du Yi Ke Da Xue Xue Bao 2014;35:379-83. |
[6] | Liu LQ, Liu YF, Yang M, et al. Effectiveness of tonifying-kidney and regulating-liver therapy on diminished ovarian reserve: a systematic review and Meta-analysis of randomized controlled trials. J Tradit Chin Med 2020;40:343-54. |
[7] | Sun YY, Tan Y, Chen SP. Effectiveness of nourishing Yin and tonifying Yang sequential therapy in combination with Climen on diminished ovarian reserve: a retrospective study. J Tradit Chin Med 2020;40:150-6. |
[8] | Kayamori T, Kosaka N, Miyamoto A, Takashi S. The differential pathways of bone morphogenetic protein (BMP)-4 and -7 in the suppression of the bovine granulosa cell apoptosis. Mol Cell Biochem 2009;323:161-8. |
[9] | Zhu GQ, Cui YH, Wang QL, Kang YG, Lü YZ, Wang JG. Bone morphogenetic proteins (BMP) 2, 4, 6 and 7 affect ovarian follicu- lar development through regulation of follicle-stimulating horm- one receptor (FSHR) and luteinizing hormone receptor (LHR) expression in goat granulosa cells. J Cell Biol Genet 2013;3:14-21. |
[10] | Ma K, Fu FZ, Jiang K, Sun LH, Cai LX. The effectiveness of Tiaojing Zhuluan decoction treating anovulatory infertility. Zhong Hua Zhong Xi Yi Jie He Za Zhi 1998;18:372-3. |
[11] | Ma K, Liu YF, He JQ, Li M, Shan J. A multi-center, randomized, double-blind clinical study on Bushen Huoxue in treatment of ovulatory dysfunction caused infertility. Zhong Guo Zhong Yao Za Zhi 2015;40:2911-5. |
[12] | Ma K. The effectiveness of Bushen Culuan decoction on ovulation and corpus luteum function in experimental rats. Fujian Zhong Yi Yao Za Zhi 1997;28:3-4. |
[13] | Zhao W, Sun GZ. The medication dosage conversion among different animals. Zhong Guo Xu Mu Shou Yi Za Zhi 2010;5:52-3. |
[14] | Zhao SG, Chen ZJ. Molecular mechanisms of major reproductive diseases. Sheng Ming Ke Xue Tong Bao 2017;29:43-51. |
[15] | Shang YJ, Chen Y, Lu S. Systemic review and Meta-analysis of Bushen Huoxue Chinese medicine in the treatment of premature ovarian failure. Zhong Yi Za Zhi 2018;59:1295-9. |
[16] | Luo X, Li X, Cheng J, et al. Systemic review and Meta-analysis of efficacy of acupuncture in the treatment of premature ovarian failure. Zhong Yi Za Zhi 2016;57:1027-32. |
[17] | Visser JA, de Jong FH, Laven JSE, Themmen APN. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2005;131:1-9. |
[18] | Yan DW, Zhou L, Sun ZY. Research progress in establishing animal models of premature ovarian failure and its evaluation indexes. Zhong Hua Yao Li Yu Du Li Xue Za Zhi 2015;29:486-92. |
[19] | Grasa P, Sheikh S, Krzys N, et al. Dysregulation of follicle development in a mouse model of premature ovarian insufficiency. Reproduction 2016;152:591-601. |
[20] | Luan Y, Edmonds ME, Woodruff TK, Kim SY. Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide. J Endocrinol 2019;240:243-56. |
[21] | Ma M, Chen XY, Li B, Li XT. Melatonin protects premature ovarian insufficiency induced by Tripterygium glycosides: role of SIRT1. Am J Transl Res 2017;9:1580-602. |
[22] | Yuan Y. Research progress of influence of bone morphogenetic protein 7 in women reproductive system and its intervention with Traditional Chinese Medicine. Guangzhou Zhong Yi Yao Da Xue Xue Bao 2019;36:297-302. |
[23] | Wang WN, Zhang WF, Li DH, et al. Lichong decoction inhibits micro-angiogenesis by reducing the expressions of hypoxia inducible factor-1α and vascular endothelial growth factor in hysteromyoma mouse model. J Tradit Chin Med 2020;40:928-37. |
[24] | Shimizu T, Magata F, Abe Y, Miyamoto A. Bone morphogenetic protein 4 (BMP-4) and BMP-7 induce vascular endothelial growth factor expression in bovine granulosa cells. Anim Sci J 2012;83:663-7. |
[1] | LI Xi, LIN Xiangquan, CHEN Dongdong, LIU Hui. B-cell lymphoma-2 phosphorylation at Ser70 site-related autophagy mediates puerarin-inhibited the apoptosis of MC3T3-E1 cells during osteoblastogenesis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 27-34. |
[2] | ZHUANG Xingxing, LIU Tao, WEI Liangbing, SONG Junmei, GAO Jiarong. Qiteng Xiaozhuo granules (芪藤消浊颗粒) medicated serum inhibits excessive proliferation and promotes apoptosis of human glomerular mesangial cells by targeting fat mass and obesity associated proteins [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1072-1080. |
[3] | XU Yani, ZHANG Yutong, HE Weile, DAI Linglin, TANG Ding, WANG Jialing, ZHANG Xufen, CHEN Qin, CHEN Lifang, WANG Zhanglian, ZHAN Mingjie. Efficiency and safety of acupuncture for women with premature ovarian insufficiency: study protocol for a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1268-1274. |
[4] | SU Chengguo, ZHAO Xiaoyan, YE Jiangnan, ZHANG Xin, JIANG Yuqing, GUO Junjie, ZHANG Xiyuan, QI Wenchuan, ZHU Jun. Effect of Tuina along “bladder meridian” alleviating intervertebral disc degeneration by regulating the transforming growth factor-β1/Smad signaling pathway in a rabbit model [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 991-1000. |
[5] | ZHU Bin, YU Ning, WANG Lei, TIAN Yue, WU Mingfen, ZHAO Zhigang. Synergistic effect of schizandrin A and DNase I knockdown on high glucose induced beta cell apoptosis by decreasing intracellular calcium concentration [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 661-666. |
[6] | JIANG Yiqian, ZHOU Xibin, PU Wenyuan, ZHOU Chunxiang. Sanwu Baisan decoction (三物白散) inhibits colorectal cancer progression in mice by remodeling gut microbiota and tumorigenesis [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 466-473. |
[7] | WANG Tianqi, LI Zining, CHEN Ting, CHEN Rui, JIN Ya, Oduro Patrick kwabena, ZHANG Han, WANG Yi. Zuogui (左归丸) and Yougui pills (右归丸) improve perimenopausal syndrome via regulation of apoptosis in mice [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 474-483. |
[8] | LIU Xueling, MA Kun, TAO Wenhua, XU Zhongkun, LIU Gang, HU Chunyan, MAO Weiwei, GU Chang, GUO Qi. Natural products for treatment of premature ovarian failure: a narrative review [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 606-617. |
[9] | XIE Jing, BI Zheng, WANG Sihai, SHEN Guoming, FANG Zhaohui. Danzhi Jiangtang capsule (丹蛭降糖胶囊) reduces renal injury in rats with diabetes induced by high fat diet and streptozotocin via downregulating toll-like receptor 4-nuclear factor-κB pathway and apoptosis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 312-321. |
[10] | DING Yajie, LIU Feng, LI Zhaoyan, Xu Yan, CAO Nida, ZHANG Guangao, WANG Rui, ZHAO Aiguang. Efficacy of luteolin on the human gastric cancer cell line MKN45 and underlying mechanism [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 34-41. |
[11] | JIANG Wen, ZHANG Wei, ZHANG Yuxiang, YANG Hao, PAN Xiaomei, CHEN Qiang, CHEN Junhui. Tilianin extracted from Xiangqinglan (Herba Dracocephali Moldovicae) inhibits apoptosis induced by mitochondrial pathway and endoplasmic reticulum stress in H9c2 cells after oxygen-glucose deprivation/reoxygenation [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 42-50. |
[12] | YANG Ye, ZHANG Aihui, LI Anmao. Celastrol promotes apoptotic cell death in children neuroblastoma cells through caspases dependent pathway [J]. Journal of Traditional Chinese Medicine, 2022, 42(6): 877-884. |
[13] | ZHENG Wei, WANG Mingxing, LIU Shanxue, LUAN Chao, ZHANG Yanqiu, XU Duoduo, WANG Jian. Buyang Huanwu Tang (补阳还五汤) protects H2O2-induced RGC-5 cell against oxidative stress and apoptosis via reactive oxygen species-mitogen-activated protein kinase signaling pathway [J]. Journal of Traditional Chinese Medicine, 2022, 42(6): 885-891. |
[14] | ZHOU Yingyan, LIANG Huasheng, YAN Jingyao, HE Xiaohong, PAN Lili, LI Xue, CHEN Xianghong, CHEN Xiumin, YANG Aicheng, HUANG Qingchun. Effectiveness and safety of tripterygium glycosides tablet (雷公藤多苷片) for lupus nephritis: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 671-680. |
[15] | YANG Mengzhe, ZHANG Beibei, LIANG Zhenqiang, CHENG Nannan, Lü Anqiao, YANG Jianyu, GUO Xingzhe, BAI Xianyu, HUANG Yuanjiao, JIAO Aijun, XU Ning. Sanguinarine suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma via inhibiting mTOR signaling [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 687-692. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
Sponsored by China Association of Chinese Medicine
& China Academy of Chinese Medical Sciences
16 Nanxiaojie, Dongzhimen Nei, Beijing, China. 100700 Email: jtcmen@126.com
Copyright 2020 Journal of Traditional Chinese Medicine. All rights reserved.